Technical Data
P4256-75M
Plasmodium vivax, CSP (P. vivax, Plasmodium vivax circumsporozoite protein)
Description:
Outside sub-Saharan Africa, where P. falciparum infection is most common, P. vivax is the most common cause of malaria infection. While not as deadly as P. falciparum, it does negatively affect human health. Malaria infection is initiated when an infected Anophales mosquito injects sporozoites into a person’s blood during a blood meal. The sporozoites migrate to and infect hepatocytes where they multiply asexually. The CSP is the major surface protein of sporozoites and form a dense coat on the parasite’s surface. The CSP is involved in the motility of the sporozoite and the invasion of target cells. It is also required for sporozoite development in the mosquito. The protein has been extensively studied as a vaccine candidate. Vaccination with irradiated sporozoites has been shown to protect against malarial parasites with the sera of protected individuals recognizing CSP.

Applications:
Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.

Hybridoma:
Sp2/0 myeloma cells with spleen cells from Balb/c mice.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG110F299Affinity Purified
SizeStorageShippingSourceHost
200ug-20°CBlue IceMouse
Concentration:
~0.5mg/ml
Immunogen:
Plasmodium vivax CSP.
Purity:
Purified by Protein G affinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.4, 0.09% sodium azide.
Specificity:
Recognizes the circumsporozoite protein (CSP) of Plasmodium vivax.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.